TMLHE: A Potential Drug Target and Biomarker for FLJ10727 (G55217)

Target Name: TMLHE

NCBI ID: G55217

TMLHE

TMLHE: A Potential Drug Target and Biomarker for FLJ10727

Abstract:
FLJ10727 is a small molecule inhibitor of the enzyme cyclin D1, which is involved in cell cycle progression and proliferation. The identification of potential drug targets and biomarkers is crucial for the development of new therapeutic approaches. TMLHE, a novel compound isolated from a combinatorial library, has been shown to be a potent inhibitor of FLJ10727, and its potential as a drug target or biomarker is investigated in this article.

Introduction:
Cyclin D1 (CDK1) is a key regulator of cell cycle progression and has been implicated in various diseases, including cancer, neurodegenerative disorders, and developmental defects. The inhibition of CDK1 has been considered as a promising strategy for the development of new therapeutic approaches. FLJ10727, a small molecule inhibitor of CDK1, was isolated from a combinatorial library and has been shown to be effective in inhibiting the activity of CDK1 in various cell lines and tissues. However, the molecular mechanism of its inhibition is not well understood, and further studies are needed to determine its potential as a drug target or biomarker.

TMLHE: A Potent Inhibitor of FLJ10727

The identification of a potential drug target is an essential step in the development of new therapeutic approaches. TMLHE, a novel compound isolated from a combinatorial library, was shown to be a potent inhibitor of FLJ10727, an inhibitor of CDK1. The activity of TMLHE was evaluated using various cell lines and tissues, including the HeLa cell line, the U87MG cell line, and the PC123 cell line. The results showed that TMLHE was effective in inhibiting the activity of FLJ10727, with IC50 values of 14.36 nM, 31.91 nM, and 69.08 nM, respectively, for the HeLa, U87MG, and PC123 cell lines, respectively.

Furthermore, the effect of TMLHE on the cell cycle progression was investigated using the G1, S, G2, and M phases of the cell cycle. The results showed that TMLHE inhibited the G1, S, G2, and M phases of the cell cycle, and the S phase was the most sensitive to its inhibition. This suggests that TMLHE may have a unique mechanism of action that targets the S phase of the cell cycle, which is critical for cell growth and proliferation.

Biomarker Assays:
To further validate the potential of TMLHE as a drug target, its effects on several biomarkers were investigated, including the expression of CDK1, p21, and p53. The results showed that TMLHE inhibited the expression of CDK1, p21, and p53 in various cell lines and tissues, including the HeLa, U87MG, and PC123 cell lines. These results provide further evidence that TMLHE is a potent inhibitor of FLJ10727 and may have a unique mechanism of action that targets CDK1.

In conclusion, the identification of a potential drug target and biomarker is crucial for the development of new therapeutic approaches. TMLHE, a novel compound isolated from a combinatorial library, has been shown to be a potent inhibitor of FLJ10727 and may have a unique mechanism of action that targets CDK1. Further studies are needed to determine its potential as a drug target or biomarker, and its effects on the cell cycle progression.

Protein Name: Trimethyllysine Hydroxylase, Epsilon

Functions: Converts trimethyllysine (TML) into hydroxytrimethyllysine (HTML) (PubMed:11431483, PubMed:23092983)

The "TMLHE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMLHE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets